Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

AZ and MSD rapidly advance Lynparza in Japan

23 October 2017 07:00 BST ASTRAZENECA AND MSD RAPIDLY ADVANCE LYNPARZA IN JAPAN WITH A SECOND REGULATORY SUBMISSION Potential to offer a new treatment option for patients withgermline BRCA-mutated, HER2-negative metastatic breast cancer   AstraZeneca and Merck & Co., Inc., Kenilworth, NJ, US (known as MSD outside the US and Canada) today announced that they have submitted a new drug application (NDA) to Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for the use of Lynparza (olaparib) tablets in unresectable or recurrent BRCA-mutated breast cancer, with a decision

Responsibility begins at the level of management — but it is part of everyone's work

The chemical industry was a model student in acorporate responsibility study by FIBS . Corporate responsibility was deemed a material issue for the business in 90% of all chemical industry companies.Kiilto believes that responsibility includes three sectors: environment and product safety, personnel and working conditions, and sustainable business operations. Kiilto prepares responsibility reports in compliance with the GRI principles, but

Nepa helps Elkjøp to capture sales opportunities

The renowned home electronics retailer and one of the biggest media buyers in the Nordics, Elkjøp is relying heavily on their advertising investments to deliver ROI. Nepa has been entrusted to help Elkjøp drive more sales to their business by identifying and recommending strategic changes in their brand- and communication activities.The rapid digitization brings about a much more fragmented media consumption. Elkjøp has seen the need to better understand the changing and more fragmented media behavior among their consumers. “Nepa’s consumer science approach to identifying and executing

Etrion Announces Successful Purchase of EUR 6.3 Million of Its Corporate Bonds

October 23, 2017, Miami, Florida, United States – Etrion Corporation (“Etrion” or the “Company”) (TSX: ETX) (OMX: ETX), a solar independent power producer, announces today that it has purchased a nominal amount of approximately EUR 6.3 million of its outstanding corporate bonds (the “Bonds”) at par value, from certain existing bondholders. These Bonds will be held by the Company as an investment and will be reported as such in its financial statements.  Following this purchase of Bonds, the Company’s annual interest cost will be EUR 2.7MM ($3.2MM) per annum, a 17 % reduction from the

Altor enters partnership with the founders of RevolutionRace

On October 18th, Altor Fund IV (“Altor”) has signed an agreement to acquire a significant minority ownership in the fast growing Swedish consumer brand, RevolutionRace, from the founders Pernilla and Niclas Nyrensten. The founders will remain as majority owners of the company and continue in their operational roles as CEO and Head of Product.RevolutionRace sells outdoor apparel products through a direct to consumer model, with an innovative design, high quality & functionality at an affordable price point. The company was founded in 2013 and has grown at an impressive speed to a turnover of

US FDA approves Bydureon BCise for type-2 diabetes

23 October 2017 07:00 BST US FDA APPROVES NEW EASY-TO-USE, ONCE-WEEKLY BYDUREON BCISE INJECTABLE MEDICINE FOR PATIENTS WITH TYPE-2 DIABETES New formulation of once-weekly exenatide in an improved device provides significant HbA1c reduction with added benefit of weight loss AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved Bydureon BCise (exenatide extended-release) injectable suspension, a new formulation of Bydureon in an improved once-weekly, single-dose autoinjector device for adults with type-2 diabetes whose blood sugar remains

Skanska sells nursing home in Gothenburg, Sweden, for about SEK 240M

Skanska has sold a nursing home under construction in Gothenburg, Sweden, for about SEK 240 million. The buyer is property fund managed by Northern Horizon and Ambea will become the tenant. The transaction will be recorded by Skanska Commercial Property Development in the fourth quarter 2017. The transfer of the property is scheduled for the spring 2019, in connection with completion.The project comprises a retirement home with 72 apartments on five floors located in the center of Angered, Gothenburg. The nursing home of about 5,300 square meters has been developed by Skanska in cooperation

Eniro announces the terms for the cash issue

This press release may not be announced, published or distributed, in whole or in part, directly or indirectly, in the United States, Canada, Japan, Australia, Hong Kong, New Zealand, Singapore, South Africa or any other country where such publication or distribution would violate applicable laws or rules or would require additional documents to be prepared or registered or require any other actions to be taken, in addition to the requirements under Swedish law. This press release is not a prospectus. For further information, please refer to “Important information” in this press release.The

FOX Networks Group Selects Ericsson for broadcast services

· Ericsson scores exclusive multi-year contract to deliver playout, media management and global distribution services for three new FOX HD channels in the Middle East · FOX and Ericsson expand existing relationship; Ericsson now supports 10 FOX television channels from its hub in Abu Dhabi · New contract further establishes Ericsson’s position as one of the world’s leading providers of broadcast and media servicesEricsson (NASDAQ: ERIC) has signed an exclusive multi-year contract with FOX Networks Group Middle East to provide playout, media management and global distribution services

Siemens’ NX provides multidisciplinary tools for product development in a unified platform

· Integration with Mentor Graphics technology provides connectivity for true multidisciplinary design · Generative design tools enable optimized organic designs, combining facet modeling with traditional models utilizing Convergent Modeling technology  · New additive manufacturing capabilities introduced for product development and 3D printing for industrial productionSiemens today announced the latest version of the company’s NX™ software.  Building on its legacy of best-in-class customer deployment readiness and data preservation, the latest version delivers the next generation of

Nitro Games signs amendment with Wargaming

The parties have agreed on a project scope increase with an amendment to the agreement signed in May 2017, resulting in approximately 0.4 MEUR increased revenue for Nitro Games.Nitro Games has signed an amendment to the game development agreement with Wargaming. The parties originally signed a mobile game production agreement in May and with this amendment the parties are amending the terms of this original agreement. Wargaming requested additional features to be introduced into the product, so the parties have agreed to increase the development budget and change the schedule and payment

Electrolux acquires Continental brand in Latin America

Electrolux today announced that the Brazilian court administering the bankruptcy of Mabe Brazil has accepted a BRL 70 million (SEK 178 million) bid to acquire the intellectual property assets of the estate. Electrolux will consequently take over the rights to the Continental brand of home appliances.Continental is a well-known, traditional brand, with a long history of supplying cooking, cooling and laundry products to Brazilian families. “Continental will be a valuable asset to Electrolux, supporting the continued profitable growth in our region,” said Ricardo Cons, Head of Electrolux

Wilson Therapeutics reaches agreement with the FDA and EMA to initiate pivotal Phase 3 FOCuS study with WTX101 in Wilson Disease

Wilson Therapeutics (publ) today announced that the discussions with the U.S Food and Drug Administration (FDA) and the European Medicines Agency (EMA), regarding the study protocol for the single pivotal Phase 3 FOCuS trial for WTX101 in Wilson Disease, have been concluded successfully. Wilson Therapeutics will now complete the preparatory work to start the trial and expects to enroll the first patient in early 2018. WTX101 (bis-choline tetrathiomolybdate) is a first-in-class copper-protein-binding agent with a unique mechanism of action, under investigation as a novel therapy for Wilson

Continued strong sales, although production disturbances in Sweden affect earnings

Inwido’s President and CEO, Håkan Jeppsson, comments the first nine months of 2017:“Inwido’s strong sales trend Inwido continues. In the third quarter, sales rose by 8 percent, and in the first nine months by 16 percent to approximately SEK 4.6 billion (SEK 4,597 million). Order bookings were in line with the third quarter of 2016 and the order backlog was 7 percent higher than at the same point last year.”  “Operating profit amounted to SEK 172 million (202), entailing an operating margin of 11.0 percent (14.0) for the quarter and 9.7 percent (11.3) for the first nine months.”  “

Interim report January-September 2017

This information is such that Inwido AB (publ) is obliged to publish in accordance with the EU market abuse regulation and the Swedish Securities Market Act. The information was submitted by the below contact persons for publication on 23 October 2017 at 7:45 a.m. CET. Sales remain strong - production disruption affects earnings Third quarter of 2017 · Net sales rose to SEK 1,559 million (1,446), representing an increase of 8 percent. Organic growth was 4 percent · EBITA amounted to SEK 172 million (212) after items affecting comparability of SEK 0 million (10), and the EBITA

Interim report jan-sep 2017: Wihlborgs continues to accelerate

· Rental income rose 11 percent to SEK 1,665 million (1,505). · The operating surplus was up 11 percent at SEK 1,256 million (1,134). · Income from property management improved 13 percent to SEK 863 million (767). · Profit for the period totalled SEK 1,495 million (1,670), corresponding to earnings per share of SEK 19.45 (21.73).“To sum up, we have completed an eventful and successful third quarter, in which we once again posted record figures for both income and earnings. At SEK 333 million, for the first time, income from property management for a single quarter exceeded SEK 300

TOMRA Q3: Preparing for Introduction of Deposit in NSW and All-Time High Sorting Order Intake

Revenues in the third of quarter 2017 amounted to 1,855 MNOK compared to 1,715 MNOK in the third of quarter 2016. This represents an increase of 8%. Adjusted for acquisitions, revenues were unchanged for TOMRA Group. The gross contribution margin was 43% in the quarter, unchanged from the third quarter of 2016. Somewhat improved margins in TOMRA Collection Solutions offset slightly lower margins in TOMRA Sorting Solutions.   The Group reported operating expenses of 496 MNOK in the third quarter, up from 408 MNOK in the third quarter of last year.  This represents an increase of 4%

A step closer to a cure for adult-onset diabetes

In healthy people, exosomes – tiny structures secreted by cells to allow intercellular communication – prevent clumping of the protein that leads to type 2 diabetes. Exosomes in patients with the disease don’t have the same ability. This discovery by a research collaboration between Chalmers University of Technology and Astrazeneca takes us a step closer to a cure for type 2 diabetes.Proteins are the body’s workhorses, carrying out all the tasks in our cells. A protein is a long chain of amino acids that must be folded into a specific three-dimensional structure to work. Sometimes,

QT GROUP PLC'S ANNUAL GENERAL MEETING AND FINANCIAL REPORTS OF PUBLICATION DATES in 2018

Qt Group Plc Stock Exchange Release October 23, 2017Qt Group Plc will publish its 2017 financial statements on February 16, 2018 at 8:00 am. The financial statements will be published as part of the company's annual report, which contains the report of the Board of Directors, consolidated and parent company financial statements, and the auditor's report for the period January 1, – December 31, 2017. At the same time the Corporate Governance Statement and the remuneration report for the financial year 2017 will be published. Qt Group Plc will publish financial reports in 2018 as

QT GROUP PLC INTERIM STATEMENT 1 JANUARY 2017–30 SEPTEMBER 2017

Third quarter: Net sales increased by 16.8 per cent   July–September 2017: · Net sales increased by 16.8 per cent year-on-year to EUR 8,718 thousand (7,467)*. At comparable exchange rates, net sales increased by 19.8 per cent. · The operating result was EUR -1,302 thousand (-899). · The operating margin (EBIT %) was -14.9 per cent (-12.0%). · Earnings per share were EUR -0.05 (-0.04). January–September 2017: · Net sales increased by 11.0 per cent to EUR 26,152 thousand (23,550) At comparable exchange rates, net sales increased by 10.9 per cent. · The operating

Multiconsult ASA – Repurchase of own shares

On 20 October 2017, Multiconsult ASA ("Multiconsult") purchased 2 728 of its own shares at an average price of NOK 87.00 per share. The shares were purchased in accordance with the Company's share repurchase programme as announced on 22 September 2017. The shares were acquired on Oslo Børs.Following this transaction Multiconsult holds 89 109 of its own shares.   For further information, please contact: Investor relations:      Mirza Koristovic, Head of Investor Relations      Phone: +47 93 87 05 25      E-mail: ir@multiconsult.no Media:      Gaute Christensen, VP

Nordic Nanovector: Presentations at European Association of Nuclear Medicine annual meeting (EANM)

Oslo, Norway, 23 October 2017 Nordic Nanovector ASA (OSE: NANO) announces the following presentations by the company’s research collaborators at the European Association of Nuclear Medicine annual meeting (EANM; 21-25 October; Vienna, Austria). Abstract:  OP-012 Title:  Pre-dosing with lilotomab prior to antibody-radionuclide conjugate therapy with 177Lu-lilotomab satetraxetan significantly increases the ratio of tumour to red marrow absorbed dose in non-Hodgkin lymphoma patients Authors:  J. Blakkisrud et al. Abstract:  OP-054 Title: Involvement of cell cycle checkpoints in

KONE to equip Melbourne's premium grade office building in Australia with UltraRope

KONE Corporation, press release, October 23,  2017KONE, a global leader in the elevator and escalator industry, has won an order to supply 21 elevators and 4 escalators to the Olderfleet development on 477 Collins Street in Melbourne, Australia. Situated in the heart of Melbourne's CBD and integrated with the Olderfleet's iconic façade, the project will house the city's newest premium grade office building designed with a best-in-class, technology-enabled future workplace in mind.With 58,444sqm of office space spanning 38 levels, the building will be 158 metres in height.

There are no items matching the current filter
There are no more items matching the current filter
Back to top